Raptor glides on promising phase II/III data in Huntington’s
By Marie Powers
Staff Writer
Staff Writer
Thursday, February 20, 2014
Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) hit a 52-week high of $17.69 Thursday after the company reported encouraging top-line results from a planned 18-month analysis of an ongoing, three-year phase II/III trial of RP103 (delayed-release cysteamine) in Huntington’s disease (HD).
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.